BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33081245)

  • 1. DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.
    Szoltysek K; Ciardullo C; Zhou P; Walaszczyk A; Willmore E; Rand V; Marshall S; Hall A; J Harrison C; Eswaran J; Soundararajan M
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
    Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
    Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
    Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
    Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.
    Munzert G; Kirchner D; Stobbe H; Bergmann L; Schmid RM; Döhner H; Heimpel H
    Blood; 2002 Nov; 100(10):3749-56. PubMed ID: 12411322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.
    Escobar-Díaz E; López-Martín EM; Hernández del Cerro M; Puig-Kroger A; Soto-Cerrato V; Montaner B; Giralt E; García-Marco JA; Pérez-Tomás R; Garcia-Pardo A
    Leukemia; 2005 Apr; 19(4):572-9. PubMed ID: 15744353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
    Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
    Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.
    Paterson A; Mockridge CI; Adams JE; Krysov S; Potter KN; Duncombe AS; Cook SJ; Stevenson FK; Packham G
    Blood; 2012 Feb; 119(7):1726-36. PubMed ID: 22160382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance.
    Iglesias-Serret D; Piqué M; Barragán M; Cosialls AM; Santidrián AF; González-Gironès DM; Coll-Mulet L; de Frias M; Pons G; Gil J
    Apoptosis; 2010 Feb; 15(2):219-29. PubMed ID: 19936928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathogenesis of chronic lymphocytic leukemia.
    Danilov AV; Danilova OV; Klein AK; Huber BT
    Curr Mol Med; 2006 Sep; 6(6):665-75. PubMed ID: 17022736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.
    Krenn PW; Hofbauer SW; Pucher S; Hutterer E; Hinterseer E; Denk U; Asslaber D; Ganghammer S; Sternberg C; Neureiter D; Aberger F; Wickström SA; Egle A; Greil R; Hartmann TN
    Cancer Res; 2016 Apr; 76(8):2186-96. PubMed ID: 26837762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
    Capitani N; Lucherini OM; Sozzi E; Ferro M; Giommoni N; Finetti F; De Falco G; Cencini E; Raspadori D; Pelicci PG; Lauria F; Forconi F; Baldari CT
    Blood; 2010 May; 115(18):3726-36. PubMed ID: 20061561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis.
    Abbaci A; Talbot H; Saada S; Gachard N; Abraham J; Jaccard A; Bordessoule D; Fauchais AL; Naves T; Jauberteau MO
    Oncogene; 2018 Feb; 37(6):756-767. PubMed ID: 29059151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia.
    Zaninoni A; Imperiali FG; Pasquini C; Zanella A; Barcellini W
    Exp Hematol; 2003 Mar; 31(3):185-90. PubMed ID: 12644014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
    Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
    Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.
    Hu X; Haney N; Kropp D; Kabore AF; Johnston JB; Gibson SB
    J Biol Chem; 2005 Mar; 280(10):9498-508. PubMed ID: 15618220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.